Relationship Between Relative Skeletal Muscle Mass and Nonalcoholic Fatty Liver Disease: A 7‐Year Longitudinal Study

Gyuri Kim, Seung‐Eun Lee, You‐Bin Lee, Ji Eun Jun, Jiyeon Ahn, Ji Cheol Bae, Sang‐Man Jin, Kyu Yeon Hur, Jae Hwan Jee, Moon‐Kyu Lee, Jae Hyeon Kim – 20 April 2018 – Nonalcoholic fatty liver disease (NAFLD) has been associated with relative skeletal muscle mass in several cross‐sectional studies. We explored the effects of relative skeletal muscle mass and changes in relative muscle mass over time on the development of incident NAFLD or the resolution of baseline NAFLD in a large, longitudinal, population‐based 7‐year cohort study.

LiverLearning®: 2018 Webinar: Cost-Effective Approach to Evaluation of Abnormal Liver Enzymes

This webinar will focus on best practices regarding evaluation of the patient presenting with abnormal liver enzymes. The focus will be not only on testing needed to arrive at the appropriate diagnosis, but also how to approach testing to minimize costs. This is an essential part of the daily practice for hepatologists and gastroenterologists.Vinay Sundaram (Moderator) Vinay Sundaram, MD, MSc is currently an Associate Professor of medicine and Director of Hepatology Outcomes Research at Cedars-Sinai Medical Center.

Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander

Manhal Izzy, Jae Oh, Kymberly D. Watt – 19 April 2018 – Cirrhotic cardiomyopathy in end‐stage liver disease is currently characterized by blunted contractile systolic response to stress with or without diastolic dysfunction in the absence of known heart disease. Since the establishment of the diagnostic criteria of cirrhotic cardiomyopathy in 2005, there have been multiple studies regarding its pathophysiology and pretransplant clinical course. The data regarding the post‐transplant course of this entity are sparse.

De Novo Hepatocellular Carcinoma Among Liver Transplant Registrants in the Direct Acting Antiviral Era

Allison J. Kwong, W. Ray Kim, Jennifer A. Flemming – 19 April 2018 – The risk of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV) receiving direct acting antivirals (DAAs) has been debated. This study aims to describe the incidence of HCC among patients listed for liver transplantation (LT) in the DAA era. Individuals with cirrhosis listed for LT from January 2003 to December 2015 were identified using the Scientific Registry for Transplant Recipients database. Patients with HCC at listing or HCC exception within 180 days were excluded.

Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy

Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger – 19 April 2018 – Congestive hepatopathy (CH) arises from chronically elevated right‐sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma.

Assessment of Advanced Liver Fibrosis and the Risk for Hepatic Decompensation in Patients With Congestive Hepatopathy

Alexander Lemmer, Lisa B. VanWagner, Daniel Ganger – 19 April 2018 – Congestive hepatopathy (CH) arises from chronically elevated right‐sided heart pressures transmitted to the liver by passive venous congestion. Over time, CH can lead to hepatic bridging fibrosis, decompensated cirrhosis, and hepatocellular carcinoma.

Subscribe to